The FDA determined the shortage of Eli Lilly And Co’s (NYSE:LLY) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) ...

S hares of Hims & Hers (NYSE: HIMS) fell as much as 15% on Thursday after news that Eli Lilly's (NYSE: LLY) GLP-1 drug was taken off the shortage list by the FDA. This could impac ...

Spirit Airlines considering bankruptcy filing - WSJ. Port strike ends as dockworkers said to agree on tentative deal with 62% ...

Bearish investors decided to classify Hims & Hers Health (HIMS) as an obesity drug supplier. HIMS stock lost 9.6% on Thursday after the U.S. Food and Drug Administration said that GLP-1, made by Eli ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Spirit shares took a nosedive on news of a possible bankruptcy filing. The budget carrier and its bondholders have discussed ...

The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...

Payrolls in focus. As the Federal Reserve is now more confident that inflation is sustainably easing toward 2%, it is ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...